CLINICAL ROLE -
FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Use in Patients With Solid Tumors
The approval offers patients with solid tumors an alternative to intravenous PD-1 inhibitor administration.
Read More
ASHP Midyear: Elevated Lp(a) Levels Pose Significant Cardiovascular Risk, Experts Emphasize Need for Awareness
Lp(a) is a critical risk factor for atherosclerotic cardiovascular disease, but current lipid-lowering therapies are largely ineffective at lowering Lp(a) levels.
Watch
Study Finds Nearly 75% of Adolescents Experience Depression, Anxiety
Female adolescents were at an increased risk of experiencing depression and anxiety symptoms compared with males.
ASHP Midyear: Bolus Dose of Antibiotic May Improve in Septic Shock
Administering first-dose antibiotics to septic shock patients via IV push rather than continuous infusion could improve the speed of antibiotic delivery and reduce logistical challenges.
Optimizing Delivery of Nimodipine in Patients With Subarachnoid Hemorrhage
This article is sponsored by Azurity Pharmaceuticals, Inc.
Because Ned Said: FDA Is Sued Over Removal of Blockbuster Weight Loss Drug From Shortages List
Some outsourcers and pharmacies have capitalized on the shortages, producing compounded versions.
Reimagining Established Drugs Medicines Could Lead to Potential New Applications
The potential treatments include ivermectin, methylene blue, glucagon-like peptide-1 receptor agonists, and low-dose naltrexone.
ASH 2024: Zanubrutinib Monotherapy, With Obinutuzimab Demonstrates Durable Efficacy and Safety in CLL/SLL
Constantine Tam, MD, discusses zanubrutinib's efficacy in CLL/SLL, emphasizing its durability, high response rates, safety considerations, and evolving therapeutic potential in combination with other agents.
MTM Updates Are Coming in 2025
Adding HIV/AIDS to core chronic diseases is a key change.
Advancing Lung Cancer Treatment With Bispecific Antibodies: A Review of Amivantamab and Tarlatamab
Bispecific antibodies amivantamab and tarlatamab hold promise for patients.
Black Patients With Asthma More Likely to Miss Scheduled Appointments for Biologic Therapies
The disparity highlights opportunities for pharmacists to get involved and address health disparities.
Patient Alleges Chain’s Opioid Policy Violates Antidiscrimination Statutes
Plaintiff argues that "blacklisting” certain individuals with opioid prescriptions was unlawful.
Transforming CLL Management: Pharmacists’ Impact on Treatment Strategies, Adherence, and Quality of Life
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia.
ASHP Midyear: Pharmacists Can Advocate for Expanded RSV Vaccination Recommendations
Pharmacists are crucial in educating patients, identifying eligible individuals, and promoting uptake of the newly expanded RSV vaccination recommendations for older adults.
Updated BNT162b2 XBB COVID-19 Vaccine Protects Against Hospitalization in Children Aged 5 to 17
Study results show that the updated BNT162b2 XBB vaccine is effective in preventing hospitalizations or emergency department visits associated with COVID-19 complications.
KRAKEN Trial Highlights Muvalaplin’s Efficacy, Safety in Reducing Lipoprotein(a)
Muvalaplin is an oral, small molecule inhibitor that can reduce lipoprotein(a).
Collective Responsibility, Confidence in Immunizations Indicate Potential of Vaccine Refusal
Individuals who refused a pneumococcal vaccine were associated with low collective responsibility and confidence in vaccine efficacy and safety.
Shaping the Future of Oncology Pharmacy Through the NCODA Medically Integrated Oncology Pharmacy Residency Program
The program develops patient-centered oncology pharmacists through comprehensive training.
Is the PASTEUR Act the Correct Way to Tackle Antibiotic Resistance?
Federal legislation would seek to foster development of antibiotics.
Cholesterol-Metabolizing Bacteria May Potentially Benefit Lipid Homeostasis, Cardiovascular Health
High levels of the Oscillibacter genus of bacteria were associated with reduced cholesterol.
ASH 2024: Cilta-Cel Achieves Sustained MRD Negativity in Patients With Multiple Myeloma
Yi Lin, MD, PhD, highlights the importance of achieving MRD negativity in multiple myeloma, CAR T-cell therapy outcomes, and the critical role of pharmacists in patient care.
Emerging BCMA-Directed Therapies in Multiple Myeloma: Bispecific Antibodies and CAR T-Cell Therapies
Here is an updated overview of the role of BCMA-directed therapies following the 2024 ASCO Annual Meeting and EHA Congress.
Ohtuvayre From Verona Pharma
Gecacitinib Demonstrates Safety, Efficacy Over Hydroxyurea in Patients With Myelofibrosis and Anemia
Gecacitinib is a novel inhibitor targeting both JAK and ACVR1.
ASHP Midyear: Biosimilars Offer Cost Savings, But Barriers to Adoption Remain
Adoption barriers include insurance coverage, patient and provider education, and regulatory hurdles that require aligned initiatives across stakeholders.
Follow Essential Steps When Reporting Medication Incidents
Proper reporting of errors and near misses helps maintain compliance and improve patient safety.
Optimizing Infusion Chair Time for Oncology Trials: Follow-Up Study
This study evaluated factors affecting the duration of the infusion appointment times for 392 clinical trial patients.
Study: Shingles Could Significantly Increase Risk of Dementia and Parkinson Disease
Researchers recommend early vaccination against herpes zoster to mitigate the risks.
ASHP Midyear: Pharmacists Play Key Role in Comprehensive COPD Management, Emphasizing Cost Considerations
Pharmacists can significantly improve chronic obstructive pulmonary disease (COPD) management by promoting non-pharmacological interventions.
Dupilumab Lowers Incidence of Psychiatric and Sleep Disorders in Patients With Atopic Dermatitis
The monoclonal antibody demonstrates the ability to reduce the incidence and improve symptoms related to sleep disorders and psychiatric disorders such as anxiety.